<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019876</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB0170</org_study_id>
    <secondary_id>CHNY-01-509</secondary_id>
    <nct_id>NCT01019876</nct_id>
  </id_info>
  <brief_title>Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases</brief_title>
  <official_title>Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduced intensity conditioning followed by allogeneic stem cell transplantation will result
      in mixed/complete donor chimerism and potentially alter the natural history and outcome of
      patients with non-malignant diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to determine the toxicity of administering a fludarabine/cyclophosphamide
      (Flu/CY) or busulfan (Bu)/Flu based conditioning regimen followed by allogeneic stem cell
      transplant (AlloSCT) in patients with non-malignant diseases.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2002</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This study is to determine the toxicity of administering a fludarabine/cyclophosphamide (Flu/CY) or busulfan (Bu)/Flu based conditioning regimen followed by allogeneic stem cell transplant.</measure>
    <time_frame>Day 30, Day 60, Day 100, 1 year, 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the risk of disease progression (including neuropsychological deterioration in patients with metabolic non-malignant diseases) following a Flu/CY or Bu/Flu based conditioning regimen.</measure>
    <time_frame>Day 30, Day 60, Day 100, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure immune reconstitution following a Flu/CY or Bu/Flu based conditioning regimen and AlloSCT in patients with selected non-malignant diseases.</measure>
    <time_frame>Day 30, Day 60, Day 100, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence and severity of GVHD following a Flu/Cy or Bu/Flu based conditioning regimen</measure>
    <time_frame>Day 30, Day 60, Day 100, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine metabolic/immune (gene/protein) reconstitution by standard biochemical/PCR assays in patients</measure>
    <time_frame>Day 30, Day 60, Day 100, 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bone Marrow Failure</condition>
  <condition>Osteopetrosis</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Severe Combined Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclohosphamide 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide 40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide 30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine/Busulfan/Alemtuzumab</description>
    <arm_group_label>Fludarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide/Fludarabine/TMG</description>
    <arm_group_label>Cyclohosphamide 200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 40</intervention_name>
    <description>Cyclophosphamide/Fludarabine/ATG/TBI</description>
    <arm_group_label>Cyclophosphamide 40</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 30</intervention_name>
    <description>Cyclophosphamide /Fludarabine/TMG</description>
    <arm_group_label>Cyclophosphamide 30</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients must meet the eligibility criteria for organ function regardless of
             diagnosis:

               -  Age &lt; 30 or = 30 years of age

               -  Adequate renal function defined as serum creatinine &lt; or = 1.5 x normal, or
                  creatinine clearance or radioisotope GFR &gt; or =40 ml/min/m2 or &gt;60 ml/min/1.73 m2
                  or an equivalent GFR as determined by the institutional normal range

          -  Adequate liver function defined as SGOT (AST) or SGPT (ALT) &lt; 5.0 x normal

          -  Adequate cardiac function defined as shortening fraction of &gt; or = 28% by
             echocardiogram, or ejection fraction of &gt; or = 48% by radionuclide angiogram or
             echocardiogram

          -  Adequate pulmonary function defined as asymptomatic or, if symptomatic, DLCO &gt;45% of
             predicted (corrected for hemoglobin level). If unable to obtain pulmonary function
             test, O2 saturation &gt;85% in room air.

        Bone Marrow Failure Syndromes

        Patients with the following diagnoses are eligible:

        Severe Aplastic Anemia:

          -  Hypocellular bone marrow biopsy (&lt;25% cellularity) and 2/3 of the following (at
             diagnosis or nadir):

          -  Absolute Neutrophil Count (ANC) &lt;200/mm3,

          -  Platelets &lt;20,000/mm3

          -  Reticulocyte count &lt;60,000/mm3

        Fanconi Anemia:

          -  Abnormal clastogenic studies (all patients)

          -  Severe Congenital Neutropenia (Kostmann's Syndrome)

          -  Amegakaryocytic Thrombocytopenia

          -  Severe thrombocytopenia (&lt; or =20,000/mm3) at diagnosis

          -  Severe depletion of megakaryocytes on bone marrow aspirate (&lt; or =25% normal)

        Diamond-Blackfan Anemia:

          -  Corticosteroid dependent for &gt; 6 months OR Transfusion dependent OR refractory
             acquired pure red cell aplasia.

          -  Infantile Osteopetrosis

          -  Schwachman-Diamond Syndrome

          -  Dyskeratosis Congenita

        Other bone marrow failure syndromes at discretion of co-principal investigators

          -  Immunodeficiencies

          -  SCIDS, all subtypes

          -  Combined Immunodeficiency Syndrome

          -  Wiskott-Aldrich Syndrome

          -  Chronic Granulomatous Disease

          -  Chediak-Higashi Syndrome

          -  Leukocyte Adhesion Deficiency

          -  Other immunodeficiencies at discretion of co-principal investigators

          -  Inborn Errors of Metabolism (IEOM)

        Transplant is recommended for the following disorders:

          -  Hurler syndrome (alpha-L-iduronidase deficiency, MPS-I), preferably before age 24
             months

          -  Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency,MPSVI)

          -  Sly syndrome (beta-glucuronidase deficiency, MPS-VII)

          -  Globoid cell leukodystrophy (galactocerebrosidase deficiency), with careful attention
             to neurologic status in the infantile form

          -  Metachromatic leukodystrophy (arylsulfatase A deficiency),juvenile or adult onset
             form; late infantile MLD only if pre-symptomatic

          -  Childhood-onset X-linked adrenoleukodystrophy (X-ALD), at initial signs of
             neuropsychological deterioration, with dietary modification prior to transplant

          -  Fucosidosis (fucosidase deficiency)

          -  Mannosidosis

          -  Aspartylglucosaminuria

          -  Niemann-Pick Disease Type B (acid sphingomyelinase deficiency) Other diagnoses may be
             considered at the discretion of the co-principal investigators

          -  For X-ALD patients greater than 5 years of age, IQ &gt;80 is required. For other patients
             greater than 5 years of age, IQ &gt; 70 is required.

          -  For Gaucher disease (glucocerebrosidase deficiency) Type I (non-neuropathic), the
             primary therapy is enzyme replacement, but allogeneic stem cell transplant has been
             used effectively.

          -  Histiocytoses

               -  Hemophagocytic Lymphohistiocytosis (HLH)

               -  Familial Erythrophagocytic Lymphohistiocytosis

               -  Langerhans Cell Histiocytosis Patients with multi-system disease whose initial
                  disease is stable or progressive after minimum 6 weeks of appropriate therapy, OR
                  Patients with recurrent multi-system disease.

               -  Malignant Histiocytosis

          -  Other non-malignant diseases not listed above may be eligible if deemed appropriate by
             the co-principal investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Garvin, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Garvin, MD, PhD</last_name>
    <phone>212 305 5872</phone>
    <email>jhg1@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William A Kim, Ph.D.</last_name>
    <phone>212-305-7213</phone>
    <email>billkim@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Garvin, MD, PhD</last_name>
      <phone>212-305-5872</phone>
      <email>jhg1@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>William A Kim, PhD</last_name>
      <phone>212-305-7213</phone>
      <email>billkim@columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Garvin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.childrensnyp.org/</url>
    <description>Click on &quot;Morgan Stanley Children's Hospital&quot; and then &quot;Clinical Services&quot; and then &quot;Blood &amp; Marrow Transplantation&quot;</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone marrow Failure</keyword>
  <keyword>Fanconi</keyword>
  <keyword>SCID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

